Monday, January 8, 2018

Impact Biomedicines Acquired By Celgene For Up To $2.35 Billion

San Diego-based Impact Biomedicines, a developer of treatments for myelofibrosis and polycythemia vera, has been acquired by Celgene Corporation, in a deal worth up to $2.35 billion. According to Celgene, it will pay approximately $1.1 billion upfront, and up to $1.25 billion in contingent payments, based on regulatory approval milestones for Impact Biomedicines' Fedratinib compound. That compound iss currently in Phase II trials with myelofibrosis patients.